Literature DB >> 1553337

Potentiation of cytotoxicity of mitoxantrone toward CHO-K1 cells in vitro by dipyridamole.

P B Desai1, R Sridhar.   

Abstract

Dipyridamole (DP), a clinically used vasodilator and an antiplatelet compound, augmented the activity of the anticancer drug mitoxantrone (MXN) toward chinese hamster ovary (CHO-K1) cells in culture. Clonogenic assays indicated that DP (1.0, 2.5, and 5.0 microM) decreased the survival of cells treated with MXN (5 to 25 nM) in a dose-dependent manner. Further, DP (1 and 5 microM) decreased the MXN concentration required for 50% inhibition of cell growth from 3.2 to 1.8 and from 3.0 to 0.5 nM, respectively, over a period of 3 days. DP (10 microM) increased the accumulation of MXN by 1.8-fold in exponentially growing cells exposed to MXN. The enhanced levels of MXN in CHO-K1 cells in the presence of the chemosensitizer may account for the potentiation of MXN-cytotoxicity by DP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553337     DOI: 10.1023/a:1018920903436

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Mitoxantrone.

Authors:  T I Poirier
Journal:  Drug Intell Clin Pharm       Date:  1986-02

2.  Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo.

Authors:  H Kusumoto; Y Maehara; H Anai; T Kusumoto; K Sugimachi
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

Review 3.  Mitoxantrone: a novel anthracycline derivative.

Authors:  J Koeller; M Eble
Journal:  Clin Pharm       Date:  1988-08

4.  Mitoxantrone affects topoisomerase activities in human breast cancer cells.

Authors:  M D Crespi; S E Ivanier; J Genovese; A Baldi
Journal:  Biochem Biophys Res Commun       Date:  1986-04-29       Impact factor: 3.575

5.  Dipyridamole enhancement of etoposide sensitivity.

Authors:  S B Howell; D K Hom; R Sanga; J S Vick; T C Chan
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

6.  Modulation of drug permeability in Chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins.

Authors:  S V Carlsen; J E Till; V Ling
Journal:  Biochim Biophys Acta       Date:  1977-06-02

7.  Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.

Authors:  J K Willson; P H Fischer; K Tutsch; D Alberti; K Simon; R D Hamilton; J Bruggink; J M Koeller; D C Tormey; R H Earhart
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

8.  Mitoxantrone in patients with acute leukemia in relapse.

Authors:  P A Paciucci; T Ohnuma; J Cuttner; R T Silver; J F Holland
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

9.  Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines.

Authors:  M Chatterjee; C N Robson; A L Harris
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

10.  Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.

Authors:  T C Chan; M Markman; S Cleary; S B Howell
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

View more
  2 in total

1.  Dipyridamole prevents triple-negative breast-cancer progression.

Authors:  Daniela Spano; Jean-Claude Marshall; Natascia Marino; Daniela De Martino; Alessia Romano; Maria Nunzia Scoppettuolo; Anna Maria Bello; Valeria Di Dato; Luigi Navas; Gennaro De Vita; Chiara Medaglia; Patricia S Steeg; Massimo Zollo
Journal:  Clin Exp Metastasis       Date:  2012-07-04       Impact factor: 5.150

2.  Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.

Authors:  G T Budd; P Herzog; R M Bukowski
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.